Bruker Corporation (BRKR)
| Market Cap | 9.57B +54.4% |
| Revenue (ttm) | 3.46B +0.4% |
| Net Income | -36.40M |
| EPS | -0.24 |
| Shares Out | 152.23M |
| PE Ratio | n/a |
| Forward PE | 27.99 |
| Dividend | $0.20 (0.32%) |
| Ex-Dividend Date | Jun 22, 2026 |
| Volume | 1,731,398 |
| Open | 64.66 |
| Previous Close | 64.34 |
| Day's Range | 61.25 - 65.30 |
| 52-Week Range | 28.53 - 65.30 |
| Beta | 1.27 |
| Analysts | Buy |
| Price Target | 59.75 (-4.92%) |
| Earnings Date | Aug 4, 2026 |
About BRKR
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron par... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for BRKR stock is "Buy." The 12-month stock price target is $59.75, which is a decrease of -4.92% from the latest price.
News
Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced it will report second quarter 2026 financial results before market opening on Tuesday, August 4, 20...
Bruker Expands Infection Detection Portfolio with Acquisition of Metagenomic mNGS DISQVER® Platform for Pathogenic Microorganisms in Blood
BREMEN, Germany--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of the DISQVER® clinical metagenomics platform from Noscendo GmbH.DISQVER® enables m...
Bruker Transcript: Jefferies Global Healthcare Conference 2026
Strong order growth in Q1 was led by semiconductor and international academic/government markets, while U.S. funding delays persist. Biopharma and security segments are robust outside the U.S., and cost-saving actions are driving margin improvements, with double-digit EPS growth expected through 2027.
Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026
WASHINGTON--(BUSINESS WIRE)---- $BRKR #BRKR--At ASM Microbe 2026, Bruker Corporation's (Nasdaq: BRKR) Microbiology & Infection Diagnostics (BMID) division is demonstrating its expanding portfolio and ...
Bruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry
SAN DIEGO--(BUSINESS WIRE)---- $BRKR #BRKR--At ASMS, Bruker Corporation (Nasdaq: BRKR) announced the launch of the new timsMRMS system, designed to empower researchers in petroleomics, sustainable fue...
Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology
SAN DIEGO--(BUSINESS WIRE)---- $BRKR #BRKR--At ASMS, Bruker Corporation (Nasdaq: BRKR) announced the launch of the unique timsMRMS system, bringing the power of trapped ion mobility separation to ultr...
Champalimaud Foundation's Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation announced the commissioning of a novel BioSpec™ 18 Tesla preclinical MRI, the world's highest-field horizontal-bore MRI system, at...
Bruker Transcript: AGM 2026
The meeting confirmed a quorum, elected three directors through 2029, approved 2025 executive compensation, and ratified the appointment of independent auditors for 2026. Stockholders were invited to submit questions before adjournment.
Bruker Earnings Call Transcript: Q1 2026
Q1 2026 results exceeded expectations with strong bookings in AI-driven and security segments, despite U.S. academic and currency headwinds. Guidance for FY2026 is reaffirmed, with margin expansion and EPS growth driven by cost savings and innovation momentum.
Bruker Earnings release: Q1 2026
Bruker released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Bruker Slides: Q1 2026
Bruker has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Bruker Quarterly report: Q1 2026
Bruker has published its Q1 2026 quarterly earnings report on May 6, 2026.
Bruker Reports First Quarter 2026 Financial Results
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced financial results for the three months ended March 31, 2026. Frank H. Laukien, Bruker's President a...
Bruker Announces Date and Time of First Quarter 2026 Earnings Release and Webcast
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced it will report first quarter 2026 financial results before market opening on Wednesday, May 6, 2026...
Bruker Spatial Biology Showcases High Fidelity Spatial Data and Integrated Multi-platform Workflows for Unprecedented Multiomic Insights at AACR 2026
SAN DIEGO--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced new updates from Bruker Spatial Biology to be showcased at the 2026 American Association for Cancer Resear...
Bruker Launches MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026
MUNICH--(BUSINESS WIRE)---- $BRKR #BRKR--At ESCMID Global 2026, the Bruker Microbiology & Infection Diagnostics division (Bruker Corporation, Nasdaq: BRKR) announces the European launch of MyGenius PR...
Bruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak Management
MUNICH--(BUSINESS WIRE)---- $BRKR #BRKR--At ESCMID Global 2026, Bruker announces important portfolio enhancements across microbial identification, outbreak analysis, and reflex next‑generation sequenc...
Bruker Unveils New NMR Products and Workflow Solutions at ENC 2026
ASILOMAR, Calif.--(BUSINESS WIRE)---- $BRKR #BRKR--At the Experimental Nuclear Magnetic Resonance Conference (ENC), Bruker Corporation (Nasdaq: BRKR) today announced new NMR products and workflow solu...
Bruker Proxy statement: Proxy filing
Bruker filed a proxy statement on April 10, 2026, providing details for shareholder voting and corporate governance matters.
Bruker Proxy statement: Proxy filing
Bruker filed a proxy statement on April 10, 2026, providing details for shareholder voting and corporate governance matters.
Bruker Invests in Photothermal AFM-IR to Advance Semiconductor Research
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced accelerated development of its photothermal AFM-IR spectroscopy capabilities to address research ch...
Bruker Announces Appointment of Thierry Bernard to its Board of Directors
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announces the appointment of Mr. Thierry L. Bernard to serve on its Board of Directors, effective as of today. Mr. ...
Bruker Accelerates the Future of Diagnostic and Prognostic Spatial Proteomics with the Launch of CellScape XR
ORLANDO, Fla.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced the launch of CellScape™ XR, a next-generation spatial proteomics platform designed to advance the developme...
Bruker Expands Collaboration with Noetik to Advance Tissue Foundational Models for Translational and Therapeutic Applications
ORLANDO, Fla.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Spatial Biology, a division of Bruker Corporation (Nasdaq: BRKR) announced today that it will expand its collaboration with Noetik Inc., followin...